SS-31

SS-31 is a synthetic peptide composed of a sequence derived from the mitochondrial protein survivin. Originally identified for its potential protective effects against mitochondrial dysfunction, SS-31 has emerged as a subject of interest in academic research due to its putative role in preserving cellular health and combating oxidative stress. This peptide is intended for use solely within the framework of scientific investigations and does not possess therapeutic applications for humans or animals.

Research Context

SS-31 was first synthesized in 2008 by a team of researchers studying its impact on mitochondrial integrity. The peptide has since been studied in vitro and in animal models for its capacity to mitigate damage associated with oxidative stress, aging, and neurodegenerative conditions. Its potential mechanisms of action include stabilization of mitochondrial membranes and enhancement of cellular resilience against metabolic stressors.

Research Overview

Research involving SS-31 has predominantly focused on its pre-clinical applications, primarily in rodent models. Studies have explored its effects on:

• Cellular senescence and aging
• Cardioprotection under ischemic conditions
• Neuroprotective effects in neurodegenerative disease models
• Preservation of mitochondrial function in metabolic disorders

While results have shown promising preliminary findings, additional translational research is required before any definitive conclusions can be drawn regarding its efficacy or safety in human applications. This peptide remains a tool for further exploration within biomedical science.

Key Research Focus Areas

• Mitochondrial Protective Effects: SS-31’s primary mechanism of action centers on the protection of mitochondrial membranes, reducing permeability transition pore (PTP) opening and associated cellular apoptosis.
• Antioxidant and Anti-Apoptotic Activity: Preliminary studies indicate its ability to modulate redox balance and inhibit oxidative damage pathways within cells.
• Neuroprotection: Investigations in animal models suggest potential benefits in reducing neurodegeneration, particularly in conditions involving mitochondrial dysfunction such as Parkinson’s disease.
• Cardioprotection: Research has examined its role in reducing cardiomyocyte damage following ischemia-reperfusion injury, though long-term cardiac outcomes remain underexplored.
• Metabolic Health: Explorations into its influence on insulin sensitivity and metabolic syndrome-related mitochondrial dysfunction are ongoing in preclinical settings.

Important Disclaimer

The information provided herein is for academic and research purposes only. This product is not intended for human or animal consumption. SS-31 is a research-use-only (RUO) peptide and should be handled with the same precautions as any other laboratory reagent. Users must comply with all applicable regulatory guidelines and ethical standards for its use in research environments. Any experimentation must be conducted under the supervision of qualified personnel adhering to institutional review protocols. For research use only. Not for human or animal consumption.